Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001782623 | SCV002024618 | likely pathogenic | not provided | 2021-10-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001782623 | SCV004667376 | pathogenic | not provided | 2023-11-21 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu554*) in the PIEZO2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PIEZO2 are known to be pathogenic (PMID: 27653382, 27843126). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PIEZO2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1324903). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV001782623 | SCV005401519 | likely pathogenic | not provided | 2024-05-16 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Prevention |
RCV004542109 | SCV004776683 | likely pathogenic | PIEZO2-related disorder | 2023-11-21 | no assertion criteria provided | clinical testing | The PIEZO2 c.1661T>A variant is predicted to result in premature protein termination (p.Leu554*). To our knowledge, this variant has not been reported in the literature or in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Nonsense variants in PIEZO2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |